SCHEMBL3979789

SCHEMBL3979789

[c]1ccc2c(c1)CC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23306 0.89
SCHEMBL22225 0.89 TSHR (0.46)
SCHEMBL467549 0.87 TSHR (0.43)
SCHEMBL5685195 0.87 TSHR (0.43)
SCHEMBL7660152 0.86 CYP2A6 (0.45)
SCHEMBL18584725 0.83 HTR2C (0.52)
SCHEMBL9251714 0.83
SCHEMBL217306 0.81 DRD2 (0.48)
SCHEMBL134194 0.80
SCHEMBL7838919 0.79 CYP2A6 (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208914-A1 AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 US claimed
US-20240043384-A1 INHIBITORS OF PU.1 FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2024-02-08 US claimed
US-20230339904-A1 ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. 2023-10-26 US claimed
US-20230094705-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME NIPPON SHINYAKU CO., LTD. (JP) 2023-03-30 US claimed
US-20230040402-A1 ANTITUMOR DRUG FOR USE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR NIPPON SHINYAKU CO., LTD. (JP) 2023-02-09 US claimed
EP-4126825-A1 AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS Janssen Pharmaceutica NV (BE) 2023-02-08 EP claimed
US-11524962-B2 Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED (US) 2022-12-13 US claimed
US-20210403472-A1 SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) PRELUDE THERAPEUTICS, INCORPORATED 2021-12-30 US claimed
US-20210317094-A1 AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-10-14 US claimed
WO-2021191391-A1 AMINOCYCLOBUTANES AS MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-09-30 WO claimed
US-10696662-B2 5-fluoro-C-(aryl or heterocyclyl)-glycoside derivatives useful as dual SGLT1 / SGLT2 modulators JANSSEN PHARMACEUTICA NV (BE) 2020-06-30 US claimed
US-20190055226-A1 5-FLUORO-C-(ARYL OR HETEROCYCLYL)-GLYCOSIDE DERIVATIVES USEFUL AS DUAL SGLT1 / SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-02-21 US claimed
US-9732066-B2 Heterocyclic derivative and pharmaceutical drug NIPPON SHINY AKU CO., LTD. (JP) 2017-08-15 US claimed
US-20160046612-A1 Heterocyclic Derivative and Pharmaceutical Drug NIPPON SHINYAKU CO., LTD. (JP) 2016-02-18 US claimed
EP-2746265-B1 HETEROCYCLIC DERIVATIVE AS MICROSOMAL PROSTAGLANDIN E SYNTHASE (mPGEs) INHIBITOR NIPPON SHINYAKU CO LTD (JP) 2015-11-18 EP claimed
US-20140221339-A1 Heterocyclic Derivative and Pharmaceutical Drug NIPPON SHINYAKU CO., LTD. (JP) 2014-08-07 US claimed
EP-2746265-A1 HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL DRUG Nippon Shinyaku Co., Ltd. (JP) 2014-06-25 EP claimed
US-20090203694-A1 INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE HURLEY TIMOTHY BRIAN 2009-08-13 US claimed
EP-2049103-A2 INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE Novartis AG (CH) 2009-04-22 EP claimed
WO-2008014311-A2 INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE NOVARTIS AG (CH) 2008-01-31 WO claimed